Sirukumab
Monoclonal antibody
N
Y (what is this?) (verify) Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]
Clinical trials
Rheumatoid arthritis
It has started clinical trials.[4] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]
Other
The drug was previously under development for the treatment of depression.[7]
See also
- Anti-IL-6
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- ^ Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278. S2CID 49330982.
- ^ a b "Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis". PR News Wire. Cision. 25 May 2011.
- ^ Clinical trial number NCT00718718 for "A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy" at ClinicalTrials.gov
- ^ House DW (16 December 2015). "Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis". Seeking Alpha.
- ^ "IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab". January 2017.
- ^ "Sirukumab - Janssen Biotech". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
